Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 12, 2007. The report details a share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,000,000 Ordinary shares
- Purchase Price: 1,314.22 pence per share
- Treasury Shares Held: 313,239,158 shares (5.49% of total voting rights)
- Shares in Issue: 5,707,433,000 shares (excluding Treasury shares)
Material Changes
The primary material change is the reduction of outstanding shares through the acquisition of 1,000,000 shares for Treasury. Consequently, the total number of shares held in Treasury increased to 313,239,158, representing 5.49% of the Company's total voting rights.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Points
- Verify the total number of shares in issue (5,707,433,000) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (313,239,158) and its percentage of voting rights (5.49%).
- Note that this filing does not contain financial performance data; refer to Form 20-F for comprehensive financial results.